Anthropic released a 42-minute investor roadshow video on Tuesday as it prepares for an expected IPO, combining its familiar safety message with a case for immense spending on computing power. The presentation repeatedly foregrounded Claude, models, customers and compute—an emphasis that reflects the cost of building and running frontier AI systems.¹

The company’s financial case is inseparable from that infrastructure push. Its amended filing projects $895 billion in compute and infrastructure spending, with nearly half expected by the end of 2030, according to Business Insider’s review. Yet Anthropic framed safety not as a brake on expansion, but as a commercial advantage: “We’re finding safety doesn’t hold us back.”¹

Then came the most arresting claim. In the roadshow, chief executive Dario Amodei said “cancer, Alzheimer’s, heart disease, mental illness” would become “relics of the past” in less than a decade.² The prediction fits Anthropic’s effort to broaden its role in drug discovery, including biotech acquisitions, its own drug-discovery work and a Bay Area wet lab focused on biology.²

But the response from medical and biotech figures was blunt. Former German health minister Karl Lauterbach said AI could aid efforts against cancer, Alzheimer’s and mental illness, but that curing them in 10 years was “impossible.” Researcher Melinda B. Chu argued Anthropic had not shown it would contribute meaningfully to those goals, while biotech executive Rami Elghandour called such claims “insane things to say in an IPO pitch.”²

That is the tension at the center of Anthropic’s sales pitch: a company presenting caution as a core value while asking investors to believe in an “age of miracles.”²